CEBP Candidate Pathways, Whole Genome Scans: Reconciling Results, Looking into the Future Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Airoldi, L.
Right arrow Articles by Riboli, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Airoldi, L.
Right arrow Articles by Riboli, E.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2118-2124, September 2005
© 2005 American Association for Cancer Research

4-Aminobiphenyl-Hemoglobin Adducts and Risk of Smoking-Related Disease in Never Smokers and Former Smokers in the European Prospective Investigation into Cancer and Nutrition Prospective Study

Luisa Airoldi1, Paolo Vineis4,5, Alessandro Colombi1, Luca Olgiati1, Carlo Dell'Osta1, Roberto Fanelli1, Luca Manzi1, Fabrizio Veglia6, Herman Autrup7, Alison Dunning8, Seymour Garte2, Pierre Hainaut10, Gerard Hoek11, Michal Krzyzanowski13, Christian Malaveille10, Giuseppe Matullo6, Kim Overvad14, Anne Tjonneland15, Francoise Clavel-Chapelon16, Jakob Linseisen17, Heiner Boeing18, Antonia Trichopoulou19, Domenico Palli20, Marco Peluso21, Vittorio Krogh3, Rosario Tumino22, Salvatore Panico23, Hendrik B. Bueno-De-Mesquita24, Petra H. Peeters12, Eiliv Lund25, Antonio Agudo26, Carmen Martinez27, Miren Dorronsoro28, Aurelio Barricarte29, M. Dolores Chirlaque30, Josè R. Quiros31, Goran Berglund32, Bengt Järvholm33, Goran Hallmans33, Nicholas E. Day9, Naomi Allen34, Rodolfo Saracci10, Rudolf Kaaks10 and Elio Riboli10

1 Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri; 2 Genetics Research Institute; 3 Department of Epidemiology, National Cancer Institute, Milan, Italy; 4 Imperial College London, London, United Kingdom; 5 University of Torino, 6 ISI Foundation, Turin, Italy; 7 Institute of Public Health, University of Aarhus, Aarhus, Denmark; 8 Department of Oncology, 9 Strangeways Research Laboratory, University of Cambridge, Cambridge, United Kingdom; 10 IARC, Lyon, France; 11 Department of Environmental and Occupational Health, Utrecht University; 12 Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands; 13 WHO, European Centre for Environment and Health, Bonn, Germany; 14 Department of Clinical Epidemiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark; 15 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; 16 Institut National de la Sante et de la Recherche Medicale U521, Institut Gustave Roussy, Villejuif, France; 17 Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 18 German Institute of Human Nutrition, Potsdam-Rehbücke, Germany; 19 Department of Hygiene and Epidemiology, Medical School, University of Athens, Athens, Greece; 20 Molecular and Nutritional Epidemiology Unit and 21 Cancer Risk Factor Branch, Molecular Biology Laboratory, CSPO-Scientific Institute of Tuscany, Florence, Italy; 22 Cancer Registry Azienda Ospedaliera Civile-M.P. Arezzo, Ragusa, Italy; 23 Dipartimento di Medicina Clinica e Sperimentale, Università Federico II, Naples, Italy; 24 Centre for Nutrition and Health, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; 25 Institute of Community Medicine, University of Tromso, Tromso, Norway; 26 Department of Epidemiology, Catalan Institute of Oncology, Barcelona, Spain; 27 Andalusian School of Public Health, Granada, Spain; 28 Department of Public Health of Guipuzkoa, San Sebastian, Spain; 29 Public Health Institute, Navarra, Spain; 30 Epidemiology Department, Regional Health Council, Murcia, Spain; 31 Public Health and Health Planning Directorate, Asturias, Spain; 32 Malmö Diet and Cancer Study, Lund University, Malmö, Sweden; 33 Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; and 34 Cancer Research UK Epidemiology Unit, University of Oxford, United Kingdom

Requests for reprints: Luisa Airoldi, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy. Phone: 39-0239014456; Fax: 39-0239001916. E-mail: airoldi{at}marionegri.it

The aim of this study was to evaluate whether biomarkers of environmental tobacco smoke exposure [i.e., 4-aminobiphenyl-hemoglobin (4-ABP-Hb) adducts] were predictive of the risk of tobacco-related cancers and diseases. We did a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, involving 190 controls and 149 cases (incident cancer of the lung, bladder, pharynx, larynx, oral cavity, leukemias, and chronic obstructive pulmonary disease or emphysema deaths). All individuals were never smokers or ex smokers for >10 years. 4-ABP-Hb adducts were analyzed in peripheral blood collected before the onset of the disease (median, 7 years). Overall, 4-ABP-Hb adducts were higher, although not statistically significantly so, in cases (as a whole) than controls. In the control population, high fruit and vegetable consumption significantly lowered the frequency of detectable adducts (Fisher's exact test, P = 0.025). Restricting the analysis to women, 4-ABP-Hb adducts were higher in cases than controls (Mann-Whitney P = 0.036) and the odds ratio (OR) for the presence/absence of adducts was 2.42 [95% confidence interval (95% CI), 1.18-4.98]. Moreover, the association of adducts with the individual cancer types was stronger in women than in the whole study population, although statistically significant only for leukemias (OR, 2.77; 95% CI, 1.06-7.20). The results provide some evidence that women may be more susceptible to environmental tobacco smoke, as suggested by their higher adduct levels. The most important finding of this prospective study is that, at least in women, 4-ABP-Hb adducts may help identify subjects at high risk of cancers related to environmental tobacco smoke exposure.




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Saletta, G. Matullo, M. Manuguerra, S. Arena, A. Bardelli, and P. Vineis
Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells
Cancer Res., August 1, 2007; 67(15): 7088 - 7094.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2005 by the American Association for Cancer Research.